Navigation Links
Orqis(R) Medical Awarded 15th U.S. Patent
Date:4/23/2008

Intellectual Property Expands to 41 Patents in more than 20 Countries

LAKE FOREST, Calif., April 23 /PRNewswire/ -- Orqis(R) Medical Corporation, a medical products company developing and marketing devices to improve cardiac performance through Aortic Flow Therapy, announced today that the United States Patent and Trademark Office has issued U.S. Patent number 7,331,921 (the '921 patent) entitled "Implantable Heart Assist System and Method of Applying Same." The '921 patent which discloses and claims methods and apparatus for intravascular renal (kidney) perfusion is exclusively owned by Orqis and is the Company's 15th U.S. Patent.

Mr. Ken Charhut, President and CEO, Orqis Medical, stated, "This latest patent is the result of Orqis' aggressive intellectual property strategy to treat the cardio-renal syndrome and improve cardiac performance with less invasive treatment approaches." He continued, "Orqis is developing a large intellectual property footprint that addresses the treatment gap between medical management and more invasive procedures without ever touching the heart."

Orqis' patent portfolio now encompasses 15 U.S. Patents and 26 International Patents in over 20 countries.

About Heart Failure

Over 5 million Americans suffer from heart failure, a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema. In the U.S., heart failure results in over 1 million hospitalizations annually and is responsible for over $33 billion in direct and indirect costs to the U.S. healthcare system each year.

About Orqis Medical Corporation

Orqis Medical Corporation is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System has secured the CE mark. The implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit orqis.com

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis Medical Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Orqis(R) Medicals MOMENTUM Trial Abstract Accepted for Late Breaking Clinical Trial Presentation at the American College of Cardiology Annual Meeting
2. Best Practice Database Adds New Research on Effective Sales Force Incentives and Continuing Medical Education
3. First-Quarter 2008 Results Teleconference/Webcast for VNUS Medical Technologies Interrupted Due to Technical Difficulties
4. Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University
5. Developing roadmaps for enhancing the professional culture of medical schools
6. UT Southwestern Medical Center receives grant from the Robert Wood Johnson Foundation
7. The Womens Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Womens Health Issues
8. Changes to Family and Medical Leave Act Clarify Employer Responsibilities
9. Medical Breakthrough Reaches America
10. CRH Medical Corporation opens third Center in Chicago
11. Medicare to consider public opinion about medical maggots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... 2017  According to the Centers for Disease Control and Prevention (CDC), ... PhysicianOne Urgent Care is helping communities across Massachusetts , ... by offering no-cost* flu shots through the end of the month. ... insurance regulations. ... get a flu shot is by the end of October, according to ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology: